Miragen Therapeutics Inc (MGEN) - Medical Equipment - Deals and Alliances Profile
- GDME279932D
- Pages: 36
- October 2018
- Total Views:1159
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.
Miragen Therapeutics Inc (MGEN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Merger 11
Signal Genetics Merges with miRagen Therapeutics 11
Equity Offering 13
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Acquisition 18
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc-Key Competitors 19
Miragen Therapeutics Inc-Key Employees 20
Miragen Therapeutics Inc-Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 22
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 24
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 26
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 28
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 30
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 32
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 34
Corporate Communications 35
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List Of Figure
List of Figures
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8
List Of Table
List of Tables
Miragen Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Signal Genetics Merges with miRagen Therapeutics 11
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc, Key Competitors 19
Miragen Therapeutics Inc, Key Employees 20
Miragen Therapeutics Inc, Subsidiaries 21
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Miragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.
Miragen Therapeutics Inc (MGEN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Merger 11
Signal Genetics Merges with miRagen Therapeutics 11
Equity Offering 13
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Acquisition 18
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc-Key Competitors 19
Miragen Therapeutics Inc-Key Employees 20
Miragen Therapeutics Inc-Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 22
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 24
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 26
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 28
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 30
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 32
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 34
Corporate Communications 35
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List Of Figure
List of Figures
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8
List Of Table
List of Tables
Miragen Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Signal Genetics Merges with miRagen Therapeutics 11
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc, Key Competitors 19
Miragen Therapeutics Inc, Key Employees 20
Miragen Therapeutics Inc, Subsidiaries 21
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Miragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.